Literature DB >> 16143730

Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function.

John H Krystal1, Edward B Perry, Ralitza Gueorguieva, Aysenil Belger, Steven H Madonick, Anissa Abi-Dargham, Thomas B Cooper, Lisa Macdougall, Walid Abi-Saab, D Cyril D'Souza.   

Abstract

BACKGROUND: In healthy individuals, ketamine hydrochloride and amphetamine sulfate produce cognitive, behavioral, and subjective effects resembling endogenous psychoses. Studying the comparative and interactive effects of these agents may provide insights into the roles of the glutamate and monoamine systems in psychosis and cognition.
OBJECTIVES: To directly compare the effects of ketamine and amphetamine and to explore their interactive effects within individuals.
DESIGN: Placebo-controlled, randomized, double-blind psychopharmacologic trial. SETTING AND PARTICIPANTS: Forty-one healthy individuals recruited from the community who completed up to 4 test days. MAIN OUTCOME MEASURES: On each test day, participants received amphetamine (a 1-minute infusion of amphetamine sulfate, 0.25 mg/kg, or saline) and ketamine (a 1-minute intravenous infusion of ketamine, 0.23 mg/kg, followed by a 1-hour infusion of 0.5 mg/kg or an identical saline bolus and infusion). The order of amphetamine and ketamine infusions was randomized.
RESULTS: At the doses studied, ketamine and amphetamine produced positive symptoms and euphoria. However, perceptual changes were produced only by ketamine, and hostility, grandiosity, and somatic concern were stimulated only by amphetamine. Amphetamine and ketamine produced conceptual disorganization, but only ketamine produced concrete ideation and unusual mannerisms. Ketamine produced negative symptoms and disrupted delayed recall. Ketamine and amphetamine showed 3 types of interactive effects: (1) amphetamine attenuated the impairment of working memory produced by ketamine; (2) amphetamine and ketamine had additive effects on thought disorder, arousal, and euphoria; and (3) amphetamine and ketamine had less-than-additive effects on psychosis.
CONCLUSIONS: These findings implicate N-methyl-D-aspartate glutamate receptors and dopamine systems in psychosis. However, glutamate and dopamine may differentially contribute to psychosis, thought disorder, and euphoria. Regarding medication development for cognitive dysfunction, the pattern of the interactive effects of ketamine and amphetamine is consistent with the hypothesis that facilitation of prefrontal cortical dopamine levels would attenuate some cognitive impairments associated with deficits in N-methyl-D-aspartate receptor function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16143730     DOI: 10.1001/archpsyc.62.9.985

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  105 in total

Review 1.  MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamine-Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective.

Authors:  Andrea de Bartolomeis; Felice Iasevoli; Carmine Tomasetti; Elisabetta F Buonaguro
Journal:  Mol Neurobiol       Date:  2014-11-14       Impact factor: 5.590

2.  Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.

Authors:  Surendra P Singh; Vidhi Singh
Journal:  CNS Drugs       Date:  2011-10-01       Impact factor: 5.749

Review 3.  N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?

Authors:  Joshua T Kantrowitz; Daniel C Javitt
Journal:  Brain Res Bull       Date:  2010-04-24       Impact factor: 4.077

4.  Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade.

Authors:  Mark R Stefani; Bita Moghaddam
Journal:  Eur J Pharmacol       Date:  2010-04-02       Impact factor: 4.432

5.  Nicotine improves working memory span capacity in rats following sub-chronic ketamine exposure.

Authors:  Samantha L Rushforth; Thomas Steckler; Mohammed Shoaib
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 6.  Glutamate-mediated excitotoxicity in schizophrenia: a review.

Authors:  Eric Plitman; Shinichiro Nakajima; Camilo de la Fuente-Sandoval; Philip Gerretsen; M Mallar Chakravarty; Jane Kobylianskii; Jun Ku Chung; Fernando Caravaggio; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero
Journal:  Eur Neuropsychopharmacol       Date:  2014-08-01       Impact factor: 4.600

7.  Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response.

Authors:  James W Murrough; Le-Ben Wan; Brian Iacoviello; Katherine A Collins; Carly Solon; Benjamin Glicksberg; Andrew M Perez; Sanjay J Mathew; Dennis S Charney; Dan V Iosifescu; Katherine E Burdick
Journal:  Psychopharmacology (Berl)       Date:  2013-09-11       Impact factor: 4.530

8.  Patterns of cognitive deficits in persons with spinal cord injury as compared with both age-matched and older individuals without spinal cord injury.

Authors:  Nancy D Chiaravalloti; Erica Weber; Glenn Wylie; Trevor Dyson-Hudson; Jill M Wecht
Journal:  J Spinal Cord Med       Date:  2018-12-03       Impact factor: 1.985

9.  Cognitive effects of intramuscular ketamine and oral triazolam in healthy volunteers.

Authors:  Lawrence P Carter; Bethea A Kleykamp; Roland R Griffiths; Miriam Z Mintzer
Journal:  Psychopharmacology (Berl)       Date:  2012-10-25       Impact factor: 4.530

Review 10.  Impaired Tuning of Neural Ensembles and the Pathophysiology of Schizophrenia: A Translational and Computational Neuroscience Perspective.

Authors:  John H Krystal; Alan Anticevic; Genevieve J Yang; George Dragoi; Naomi R Driesen; Xiao-Jing Wang; John D Murray
Journal:  Biol Psychiatry       Date:  2017-01-13       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.